After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

Last year, AbbVie decided to walk away from a pact with gene editing biotech Editas that was originally penned via its new buyout, Allergan.

Now, the Big Pharma is back in the CRISPR biotech game, signing up to a new deal with Editas’ rival Caribou Biosciences, although this research deal goes further.